Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54

OBJECTIVE: To investigate the efficacy, safety and immunogenicity of PF-06438179/GP1111 (PF-SZ-IFX) compared with European reference infliximab (Remicade(®); ref-IFX) in patients with moderate-to-severe, active rheumatoid arthritis after continued long-term use of PF-SZ-IFX, and in patients who were...

Descripción completa

Detalles Bibliográficos
Autores principales: Alten, Rieke, Batko, Bogdan, Hala, Tomas, Kameda, Hideto, Radominski, Sebastiao C, Tseluyko, Vira, Babic, Goran, Cronenberger, Carol, Hackley, Sarah, Rehman, Muhammad, von Richter, Oliver, Zhang, Min, Cohen, Stanley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446180/
https://www.ncbi.nlm.nih.gov/pubmed/30997153
http://dx.doi.org/10.1136/rmdopen-2018-000876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446180/
https://www.ncbi.nlm.nih.gov/pubmed/30997153
http://dx.doi.org/10.1136/rmdopen-2018-000876

Ejemplares similares